Nanosphere Health Sciences Inc NSHSF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $0.01
- Day Range
- $0.02–0.02
- 52-Week Range
- $0.00–0.20
- Bid/Ask
- $0.00 / $0.10
- Market Cap
- $205,504.10
- Volume/Avg
- 15,000 / 3,915
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Nanosphere Health Sciences Inc is a nano-biotechnology company. The company is focused on providing next-generation delivery of nutritive elements and medications. Its NanoSphere Delivery System platform technology addresses the problems of low bioavailability and excessive dosage amounts of a wide range of bioactive compounds. It focuses on developing nanoencapsulation technology for the delivery of nutritive elements and medicants through licensing arrangements.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- —
- Website
- —
Valuation
|
Metric
|
NSHSF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
NSHSF
Financial Strength
|
Metric
|
NSHSF
|
|---|---|
Quick Ratio | 0.01 |
Current Ratio | 0.01 |
Interest Coverage | — |
Quick Ratio
NSHSF
Profitability
|
Metric
|
NSHSF
|
|---|---|
Return on Assets (Normalized) | −570.21% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
NSHSF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Zlhpnwxv | Vqjv | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gcbjjftn | Bvmmv | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rzgjcnsry | Dxkwhy | $99.5 Bil | |
MRNA
| Moderna Inc | Wghrxjyb | Nmtk | $38.8 Bil | |
ARGX
| argenx SE ADR | Tywscrkbr | Dmmj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Xnbcqfzk | Zbbx | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Pcjqprlf | Xvjhb | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jwrtyxtf | Zzjgjl | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Zfkdjxlk | Gzvxfk | $12.5 Bil | |
INCY
| Incyte Corp | Shsdlrsp | Btmdncj | $11.6 Bil |